A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
Galactorrhea and amenorrhea are known risks of risperidone, given risperidone's blockade of dopamine D2 receptors and subsequent risk of prolactin elevation, and this paper presents the case of an adolescent female patient who developed reversible amenorrhea and galactorrhea after being treated with risperidone 0.25 mg twice a day for three months. Her prolactin levels and pituitary MRI were normal and the patient's menstrual cycles returned to normal after risperidone was discontinued. Thisdoi:10.1080/2331205x.2017.1328819 fatcat:4op6ppw6tfbqdkavhwopqxfxkq